Top Story

Incidence, prevalence of neuroendocrine tumors on the rise

April 27, 2017

Incidence and prevalence of neuroendocrine tumors are steadily rising, possibly due to better detection of early-stage disease and stage migration, according to a retrospective, population-based study published in JAMA Oncology.

“We found that age-adjusted annual incidence of neuroendocrine tumors increased from 1.09 per 100,000 [individuals] in 1973 to 6.98 per 100,000 in 2012, a 6.4-fold increase,” Arvind Dasari, MD, MS, assistant professor of gastrointestinal oncology at The University of Texas MD Anderson Cancer Center, and colleagues wrote. “Survival of patients with neuroendocrine tumors has improved over time, and this increase was especially pronounced in distant gastrointestinal ... and in distant pancreatic neuroendocrine tumors, reflecting improvements in therapies for those sites.”

FDA News

FDA grants breakthrough therapy designation to lorlatinib for ALK–positive NSCLC

April 27, 2017
The FDA granted breakthrough therapy designation to lorlatinib for the treatment of patients with anaplastic lymphoma kinase–positive metastatic non–small…
In the Journals Plus

Clofarabine shows promise as alternative chemotherapy for younger patients with AML

April 27, 2017
Clofarabine-based combination therapy may serve as a new option for chemotherapy among younger patients with acute myeloid leukemia in their first remission, study data
In the Journals Plus

Cranial radiotherapy linked to subsequent meningiomas in childhood cancer survivors

April 27, 2017
The diagnosis of meningioma in childhood cancer survivors exposed to cranial radiotherapy increased risk for neurologic morbidity, according to a cohort study published…

Memorial Sloan Kettering Cancer Center names head of solid tumor oncology

April 26, 2017
Luis A. Diaz, MD, has been named head of the division of solid tumor oncology in the department of medicine at Memorial Sloan Kettering Cancer Center. Diaz —…
More News Headlines »

Individualized Prophylaxis in Hemophilia

Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals

This program will provide education for hematologists, nurses, pharmacists, and other healthcare providers involved in…
More »
Meeting News

VIDEO: Speaker compares single-agent vs. combination immunotherapy for melanoma

April 9, 2017
More »
American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting


What's Hot in Melanoma? Highlights from the HemOnc Today Melanoma and Cutaneous Malignancies 2017 Meeting

This activity is supported by an educational grant from Merck & Co, Inc.

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the…
More »
Current Issues
View the Current Issue
HemOnc Today